Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | PLAUR | Q03405 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077282 | 0.85 | SIGMAR1 (0.38) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL1401532 | 0.85 | SIGMAR1 (0.38) | SIGMAR1OPRD1SLC6A4 | |
| SCHEMBL1905214 | 0.84 | SIGMAR1 (0.47) | SIGMAR1SLC6A4CA12CA1CA2 | |
| SCHEMBL7842583 | 0.84 | SIGMAR1 (0.38) | SIGMAR1OPRD1CHRM5CHRM3CA12 | |
| SCHEMBL4559648 | 0.82 | SIGMAR1 (0.43) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL10413132 | 0.82 | SIGMAR1 (0.43) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL1900357 | 0.81 | SIGMAR1 (0.58) | SIGMAR1OPRD1CHRM5CHRM3CA12 | |
| SCHEMBL4557394 | 0.80 | MEN1 (0.39) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL6032886 | 0.80 | SIGMAR1 (0.41) | SIGMAR1OPRD1SLC6A4PLAUPLAUR | |
| SCHEMBL9162742 | 0.79 | PLAU (0.36) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240415921-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2024-12-19 | — | — | US | disclosed |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3875082-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3858341-A1 | PSMA LIGAND-CONTAINING CONJUGATES FOR THE TREATMENT OF PROSTATE CANCER | Endocyte, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210024581-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014085575-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014078484-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014062697-A2 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING | ENDOCYTE, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCTYE, INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2176293-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | Endocyte, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009002993-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1071668-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Du Pont Pharmaceuticals Company (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054308-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SIGMAR1 4521/4885OPRD1 3961/4885DPP7 195/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SIGMAR1 4521/4885OPRD1 3961/4885DPP7 195/4885 |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | SIGMAR1 2222/4885OPRD1 2638/4885DPP7 3425/4885 |
| US-20210024581-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | SIGMAR1 1097/4885OPRD1 3066/4885DPP7 1849/4885 |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SIGMAR1 4521/4885OPRD1 3961/4885DPP7 195/4885 |
| US-20240415921-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | SIGMAR1 2222/4885OPRD1 2638/4885DPP7 3425/4885 |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | SIGMAR1 4521/4885OPRD1 3961/4885DPP7 195/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | SIGMAR1 4521/4885OPRD1 3961/4885DPP7 195/4885 |
| US-20100323973-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | SIGMAR1 1097/4885OPRD1 3066/4885DPP7 1849/4885 |
| US-20140073761-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | CD44, HAVCR2, HCAR1 | SIGMAR1 1097/4885OPRD1 3066/4885DPP7 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.